Unlike other intellectual property agreements, the TRIPS Agreement has a powerful enforcement mechanism. States can be sanctioned by the WTO dispute settlement mechanism. Since the entry into force of travel, it has been criticized by developing countries, scientists and non-governmental organizations. While some of these criticisms are directed at the WTO in general, many proponents of trade liberalization also view the TRIPS Agreement as bad policy. The effects of concentrating the wealth of TRIPS (the movement of money from people in developing countries to copyright and patent holders in developed countries) and the imposition of artificial scarcity on citizens of countries that would otherwise have had weaker intellectual property laws are common grounds for such criticism. Other criticisms have focused on TRIPS` failure to accelerate the flow of investment and technology to low-income countries, an advantage promoted by WTO members in the run-up to the agreement`s creation. World Bank statements suggest that the TRIPS Agreement has not led to a demonstrable acceleration of investment in low-income countries, although it may have done so for middle-income countries. [33] Long TRIPS patent terms have been investigated to unduly slow down generic substitutes market entry and competition. In particular, the illegality of preclinical studies or the submission of samples for approval until a patent expires has been accused of having led to the growth of a few multinationals rather than producers in developing countries.

The TRIPS Agreement introduced intellectual property law into the multilateral trading system for the first time and remains the most comprehensive multilateral agreement on intellectual property to date. In 2001, developing countries, concerned that developed countries were insisting on too narrow an interpretation of TRIPS, launched a round table that resulted in the Doha Declaration. The Doha Declaration is a WTO declaration that clarifies the scope of the TRIPS Agreement and states, for example, that the TRIPS Agreement can and should be interpreted in terms of the objective of “promoting access to medicines for all”. The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international agreement between all member states of the World Trade Organization (WTO). .